Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1994, Vol.34 (2), p.171-174
Main Authors: Friedman, H S, Houghton, P J, Schold, S C, Keir, S, Bigner, D D
Format: Article
Language:English
Subjects:
Adult
Animals
Antineoplastic Agents - therapeutic use
Antineoplastic Agents - toxicity
Camptothecin - analogs & derivatives
Camptothecin - therapeutic use
Camptothecin - toxicity
Central Nervous System Neoplasms - drug therapy
Central Nervous System Neoplasms - mortality
Child
Drug Screening Assays, Antitumor
Female
Humans
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Random Allocation
Time Factors
Topotecan
Transplantation, Heterologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1-5 and 8-12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts--D-456 MG (28.6% increase) and D-54 MG (39% increase)--treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors.
ISSN:0344-5704
1432-0843
DOI:10.1007/bf00685936